Navigation Links
Lymphoma in Medical Technology

Northern California Cancer Center's First-of-Its-Kind Research Reveals Low Socioeconomic Status Often Equals Poor Chance of Lymphoma Survival

... with substantially poorer survival" of follicular lymphoma in California. Although survival rates ... that among all patients diagnosed with follicular lymphoma in California, those in poorer neighborhoods had ... sweating and fatigue. It is called "follicular" lymphoma because lymph nodes seen under microscopes ...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... trial") is being presented at the Pan Pacific lymphoma conference by Dr. Richard Van der Jagt of the ... Clinical Studies in Indolent non-Hodgkin's lymphoma Additionally, data from two previously ... therapy with CHOP-R. The Pan Pacific lymphoma Conference poster is available at ...

Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial

... out of three patients with refractory or relapsed lymphoma - Phase III study underway to explore ... with the most common type of non-Hodgkin's lymphoma EAST HANOVER, N.J., June 8 /PRNewswire/ -- ... in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease(1). Based on results ...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

... #e14591; Publication only. Non-Hodgkin's lymphoma Kingsley E, et al. An open-label, ... untreated, grade I-II, follicular Non-Hodgkin's lymphoma (FL). Abstract #8582; Poster Board #S11; lymphoma and Plasma Cell Disorders, May 30, 8:00 ...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

... other investigational uses, there was one case of lymphoma among 2,657 CIMZIA-treated patients and one case of Hodgkin lymphoma among 1,319 placebo-treated patients. In CIMZIA ... and open label) a total of three cases of lymphoma were observed among 2,367 patients. This is ...

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

... with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). This is the first Btk selective ... validation of Btk as a target in lymphoma was generated using PCI-32765 in a mouse model of B-cell receptor-driven lymphoma and in spontaneous ...

Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas

... with refractory or relapsed peripheral T-cell lymphoma (PTCL). The clinical trial's primary objective ... suffering from this subset of non-Hodgkin's lymphoma that originates in the patient's T-cells. Prior ... may offer new hope to the 12-15% of non-Hodgkin's lymphoma patients with the T-cell variety," said Elliott ...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

... results in salvage therapy of non-Hodgkin's lymphoma in heavily pretreated patients and several years ... patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who ... to ensure that those patients with non-Hodgkin's lymphoma who do not respond to current available therapies ...

The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML

... N.J., Jan. 22 /PRNewswire/ -- The Leukemia & lymphoma Society (LLS) and Celator Pharmaceuticals, Inc. ... "We are very pleased that The Leukemia & lymphoma Society sees the potential of CPX-351 and is ... and 8,820 deaths. About The Leukemia & lymphoma Society The Leukemia ...

New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia

... regimens in the treatment of chronic lymphocytic lymphoma (CLL). Promising results have been reported with ... in patients with relapsed or refractory indolent lymphoma Robert Rifkin, M.D., Rocky Mountain ... clinical activity in diffuse large B-cell lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (CLL) ...

Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months

... for patients with follicular B-cell non-Hodgkin's lymphoma who achieved a response to first line therapy ... in patients with follicular B-cell non-Hodgkin's lymphoma who had achieved a partial remission (PR) or a ... for more information. About Non-Hodgkin's lymphoma ...

The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial

... N.Y., Dec. 3 /PRNewswire/ -- The Leukemia & lymphoma Society (LLS) and Memgen, LLC jointly announce ... . About The Leukemia & lymphoma Society The Leukemia & lymphoma Society(R), headquartered in White Plains, NY, ...

Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma

... treatment in follicular non-Hodgkin's lymphoma patients. Addition of the Zevalin therapeutic ... treatment of follicular non-Hodgkin's lymphoma patients may enhance the depth of response, even ... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ...

Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma

... untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a ... with CD20-positive follicular non-Hodgkin's lymphoma who had achieved a partial response or a complete ... low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab ...

Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment

... More cases of malignancies including lymphoma have been observed among patients receiving a TNF ... Furthermore, there is an increased background lymphoma risk in rheumatoid arthritis patients with ... Rare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with ...

Queen's University Chooses Xceed's Ziplex(R) System for Translational Research

... for one in four of all cases, follicular lymphoma is a slow-growing cancer that arises from ... President and CEO, David Deems. "Her follicular lymphoma research, which includes the use of both archival ... expression levels in primary follicular lymphoma were correlated with a five-year outcome. The ...

Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156

... Chronic Lymphocytic Leukemia, Small Lymphocytic lymphoma and Follicular Lymphoma." It is being conducted ... leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL), and to ... "Preliminary evidence of activity in lymphoma was observed in phase 1 studies with AEG35156," ...

Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma

... indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to treatment with TREANDA(R) ... with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab ... (or slow growing) and aggressive. Indolent B-cell lymphoma and mantle ...

University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society

... Friedberg's work on a new targeted treatment for lymphoma patients. Dr. Friedberg is studying the drug ... with indolent and mantle cell non-Hodgkin lymphoma (NHL). This drug inhibits the molecule called SYK, which controls the survival of B-cells in lymphoma patients. Dr. Friedberg has already shown in ...

The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial

... is very pleased to be working with The Leukemia & lymphoma Society. ISF35 has the potential to become a ... http://www.memgenbio.com . About The Leukemia & lymphoma Society The Leukemia & lymphoma Society(R), headquartered in White Plains, ...

Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma

... Oral presentation at international lymphoma conference shows investigational regimen ... and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics, Inc. (CTI) (Nasdaq ... patients with high risk diffuse large B-cell lymphoma (DLBCL) relapse after treatment with ...

Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma

... in patients with multiply recurrent non-Hodgkin's lymphoma (NHL) who were treated with motexafin ... stereotactic radiosurgery. "These results in lymphoma are consistent with motexafin gadolinium's known ... of Pharmacyclics, and a co-author on the lymphoma study. Zevalin is a radiolabeled antibody ...

Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL

... Results to be Presented at lymphoma Meeting in Lugano, Switzerland SOUTH SAN ... leukemia (SLL/CLL) or from diffuse large B-cell lymphoma (DLBCL), particularly in view of the advanced ... at the 10th International Conference on Malignant lymphoma in Lugano, Switzerland later this week. Rigel ...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

... in relapsed multiple myeloma and mantle cell lymphoma (MCL). "These data, as well as the results from ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ... with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In ...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

... with relapsed and/or refractory mantle cell lymphoma (MCL), a form of non-Hodgkin's lymphoma, treated ... in Chicago. "Relapsed/refractory mantle cell lymphoma is extremely difficult to treat, and this is the ... temsirolimus in relapsed/refractory mantle cell lymphoma and indicate that mTOR inhibition may be a viable ...

Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... am - 12:00 pm CST, General Poster Session: lymphoma and Plasma Cell Disorders, S Hall A1, ... in Aggressive B-Cell Non-Hodgkin's lymphoma (Abstract 8563) Presentation: Saturday, ... am - 12:00 pm CST, General Poster Session: lymphoma and Plasma Cell Disorders, S Hall A1, ...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

... with renal insufficiency. Non-Hodgkin's lymphoma (NHL) Beyond multiple myeloma, the Company ... patients with previously treated mantle cell lymphoma (MCL), the most aggressive form of NHL. ... 45,000 deaths annually. About Non-Hodgkin's lymphoma (NHL) and Mantle ...

The Leukemia & Lymphoma Society and Anjin Group Announce Multi-Year Collaborative Research Agreement

... . About The Leukemia & lymphoma Society The Leukemia & lymphoma Society(R), headquartered in White Plains, ... in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 ...

Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma

... of patients with follicular lymphoma - CAMBRIDGE, Mass., Feb. 20 ... approved by the FDA to treat relapsed mantle cell lymphoma (MCL). MCL is an aggressive, rapidly ... with follicular and marginal zone lymphoma and 10,000 with MCL. There are approximately ...

Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

... patients with relapsed or refractory Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL). Patients will receive 75 mg/m2 of Vidaza ... approved therapies in relapsed/refractory Hodgkin lymphoma for decades. As epigenetics is thought to play a ...

Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

... with relapsed or refractory peripheral T-cell lymphoma (PTCL), and has recommended that the trial ... Development & Malignancy Program and Chief, lymphoma Service, Columbia University, Herbert ... designation to PDX for the treatment of T-cell lymphoma in July 2006 and granted fast track designation ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... in Patients with Newly Diagnosed T-Cell lymphoma - Barbara Pro, M.D. Anderson Cancer Center, ... Years Old with Untreated Diffuse Large B Cell lymphoma (DLBCL) - Maria Alma Rodriguez, University of ... for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. ...

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

... in multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). (Logo: ... 45,000 deaths annually. About Non-Hodgkin's lymphoma and Mantle Cell Lymphoma NHL is the most common ... with follicular and marginal zone lymphoma and 10,000 with MCL. There are approximately ...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

... with advanced solid tumors or non-Hodgkin's lymphoma (NHL). "We are pleased to advance the ... . About Non-Hodgkin's lymphoma Non-Hodgkin's lymphoma (NHL) is the most common hematological cancer and ...

The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals

... among adult blood cancer patients, The Leukemia & lymphoma Society and Cleveland Clinic Taussig Cancer ... access to the newest treatments for leukemia, lymphoma and myeloma. "The challenge of recruiting ... . About The Leukemia & lymphoma Society The Leukemia ...

Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma

... relapsed or refractory peripheral T-cell lymphoma (PTCL). Results of the interim analysis of ... Comprehensive Cancer Center and Chief of the lymphoma Service at NewYork-Presbyterian Hospital, is the ... drug designation to PDX for treatment of T-cell lymphoma in July 2006 and granted fast track designation ...

The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients

... to their doctor first." About The Leukemia & lymphoma Society The Leukemia & lymphoma Society, headquartered in White Plains, NY, with ... in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society ...

September is Leukemia, Lymphoma and Myeloma Awareness Month

... will die from one this year. The Leukemia & lymphoma Society is a beacon of help and guidance to those ... and each September the Society observes Leukemia, lymphoma and Myeloma Awareness Month, to shed light on ... 9 a.m. to 6 p.m. ET. About The Leukemia & lymphoma Society The Leukemia ...

Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma

... as an Orphan Drug for the treatment of Hodgkin's lymphoma in the United States. Criteria for designation ... trial in relapsed and refractory Hodgkin's lymphoma were presented at the American Society of ... in hematological malignancies. About Hodgkin's lymphoma ...

CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs

... for Injection against solid tumors and lymphoma remains open for enrollment and is continuing to ... single agent activity against peripheral T-cell lymphoma and cutaneous T-cell lymphoma, as well as the ... Updated results cell lymphoma anticipated Q4 2007 Belinostat ...
Other Contents
(Date:8/11/2015)... 2015 Today, ZUK announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1155 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... prominent smartphone manufacturer in China ... FPC1 155 for Z1 , ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
(Date:8/30/2015)... ... 2015 , ... Scientists in France say asbestos exposure may put workers at ... Mesothelioma has just posted an article on the new research. Click here to ... incidence among 2,024 French asbestos plant workers from 1978 to 2009. In addition to ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the ... (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” , The ... PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E Park Ave., ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale Avene ... , “Before, a threshold of $49.00 was required to qualify for free standard shipping,” ... free standard shipping for customers regardless of the item’s selling price.” , With competitive ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of ... an entire short segment to the subject of diabetes. Diabetes is a debilitating health ... basis, but recent advancements in medical science may prove to be a significant breakthrough ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
Other TagsOther Tags